Abdi İbrahim

Company Profile*Today’s Abdi IbrahimShareholders The Barut and Esirtgen Families

Abdi Ibrahim Tower Istanbul, Turkey

Production and R&D Esenyurt, Istanbul

Turnover 480 Million USD

Production Capacity 350 Million Units

Product Range 56% Original Pharmaceuticals44% Generic Pharmaceuticals

Licensors ~ 30 International Companies

Employees ~ 3.000

* As of December 2015

Industry Leader in Turkey since 2001

Turkish Pharmaceutical Market Development

1,561,71 1,76 1,77 1,82

1,95

2010 2011 2012 2013 2014 2015

Billion Units

13,0613,3212,6813,4114,59

16,87

2010 2011 2012 2013 2014 2015

Billion TL

8,677,98

7,04 7,05 6,676,21

2010 2011 2012 2013 2014 2015

Billion USD

Abdi İbrahim Market Share in Turkey

8,11%

6,30%

5,56%

5,34%

5,05%

3,76%

3,39%

3,15%

3,13%

2,87%

ABDİ İBRAHİM

BILIM

BAYER

EASTPHARMA

SANOFI

İBRAHİM ETEM

GLAXOSMITHKLINE

NOVARTIS

SANTA FARMA

ASTRAZENECA

Market Share – Units (2015)

6,08%

6,04%

4,38%

4,22%

4,10%

3,27%

3,26%

2,95%

2,84%

2,68%

ABDİ İBRAHİM

NOVARTIS

PFIZER

SANOFI

BAYER

BILIM

GLAXOSMITHKLINE

ASTRAZENECA

EASTPHARMA

ROCHE

Market Share - $ Turnover (2015)

Ref: IMS

INTERNATIONAL MARKETS AT A GLANCE

Abdi İbrahim is strategically present in 6 countries

Local JV, manufacturing sites, operation more than

10 years with own sales forceAlgeria

Kazakhstan

Rep office with own sales forceAzerbaijan

Georgia

Direct management of sales and marketing

teams by Aİ under payroll of distributors

IraqAlbania

AlgeriaIraq

AzerbaijanGeorgia

Albania

Kazakhstan

Production Facilities

Algeria (under construction)Production Capacity 12 million boxes

Total Closed Area 6.000 sqm

Production Area 5.500 sqm

Employees > 80

Pharmaceutical Forms Solid and liquid

KazakhstanProduction Capacity 8 million boxes

Total Closed Area 11.600 sqm

Production Area 7.000 sqm

Employees > 70

Pharmaceutical Forms Solid dosages

Abdi İbrahim in the World*Abdi Ibrahim Affiliates (Own companies, factories, sales forces)

Algeria Azerbaijan Albania

Kazakhstan Georgia Iraq

Other Countries (Operation through distributor, products sold with Abdi İbrahim Brands)

GCC UK Germany Afganistan

Jordan Netherlands Czech Republic Portugal

Libya Bosnia Turkmenistan Yemen

Kosova

Out-licensing Countries (products developed at Abdi İbrahim but sold with customer brands)

EU Countries Canada Lebanon S.Korea

Russia Tunisia Belarusia Colombia

Ukraine Morocco S.Africa

Turnover: *63 million USD* ≈ 2015 annual gross turnover

International Markets Gross USD Sales Development

-

20,00

40,00

60,00

80,00

100,00

120,00

140,00

2012 2013 2014 2015 2016 2017

SalesUSD

31 M 52M 52M 63M 90M 133M

The Worldwide availability of Abdi Ibrahim Registered Products *

56%11%

11%

19%1% 2%

CISBALKANSMENA & Sub-Saharan AfricaEUCANADAFAR EAST

*number of MAs

R&D, Manufactuıring & Licensing(Capabilities)

The first and the largest accredited R&D center in Turkish Pharma Industry

5% of turnover allocated to R&D activities

Advantageous location for “Day1” launches in EU

Experience in conducting co-development projects with several European companies and worlwide experience in registration

WHO’s GMP standards are used in studies conducted with state of the art equipments

Innovative approaches to design formulations and manufacturing processes (industry leader in patent applications)

R&D Excelence

R&D Excelence

ABDI’S CORE PLATFORM

TECHNOLOGIES

DERMAL

CREAMS , GELS, POMADES,

OINTMENTS, NAIL LACQUERS,

SUPPOSITORIES

EFFERVESCENT TECHNOLOGY

EFFERVESCENT TABLETS, SACHETS

EMULSION TECHNOLOGY

HOMOGENISATION TO MAKE

EMULSIONS USING HIGH PRESSURE HOMOGENIZERS

INHALATION TECHNOLOGY

DPI FORMULATIONS FOR DELIVERING DRUG TO LUNGS

MODIFIED RELEASE DOSAGE FORMS

DELAYED RELEASE EXTENDED RELEASE

SUSTAINED RELEASE

NANO TECHNOLOGY

NANONIZATION OF DRUG TO MEET QTPP

PARENTERAL

DELIVERY FOR VARIOUS

CLASSES OF DRUGS

PRESCRIPTION PRODUCTS

OTC PRODUCTS

EXPERTISE IN DEVELOPING SINGLE AND MULTIPLE DRUGS IN A DOSAGE FORM AS WELL AS FIXED DOSE COMBINATIONS

R&D Excelence

Experience in manufacturing of nearly 200 molecules in solid, semi-solid, liquid galenic forms

Annual capacity of 350 million packs in Turkey

BfarM, Danish Medicine Agency, GCC, Canada, Ukraine, MCC, Infarmed, Korea and several other authority and customer audits and approvals

Experience in manufacturing with deadlines and making “Day 1 launches” for off-patent products

Supply to 50 countries including several EU states with several SKUs

Manufacturing Excelence

Compliance with special authority needs in terms of packaging(Bollino, 2d barcoding, vignette etc.)

Support in providing stability studies in different climatic zones

Production possibilities such as multilayer tablets , sachets & efervescants

Flexibility in lead times

The largest and brand-new technologistic center in Turkish Pharma Industry (35M USD invested)

Current manufacturing capability in Kazakhistan & Turkey & Algeria Soon biotech manufacturing option in Turkey

Manufacturing Excelence

Direct out-licensing deals with multinational companies like Mylan, Stada, Sanofi, Aspen and deals with local leaders like Pharmaline, Teriak, Bottu, Propharma & Delta Medical,Camox, Tchaikapharma, Dr.Max Pharma, Orifarm, Banaja, Mint & Riva

Runed several DCPs for EU & Canada , product under registration in GCC

Decades of experience in working with licensores & possible synergies

Out-licensing department with dedicated key account managers

Licensing Excelence